Safety, Tolerability and Pharmacokinetics of Yimitasvir Phosphate Capsule, a Novel Oral Hepatitis C Virus NS5A Inhibitor, in Healthy Chinese Volunteers
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Drug Investigation"
DOI: 10.1007/s40261-019-00791-8
Abstract: Background and ObjectivesYimitasvir is a novel oral hepatitis C virus non-structural protein 5A (NS5A) inhibitor. The aims of this first-in-human study were to evaluate the safety, tolerability and pharmacokinetics of single and multiple doses of… read more here.
Keywords: oral hepatitis; ns5a inhibitor; safety tolerability; novel oral ... See more keywords
Prodrug Strategies to Improve the Solubility of HCV NS5A Inhibitor Pibrentasvir (ABT-530).
Sign Up to like & getrecommendations! Published in 2020 at "Journal of medicinal chemistry"
DOI: 10.1021/acs.jmedchem.0c00956
Abstract: A research program to discover solubilizing prodrugs of HCV NS5A inhibitor pibrentasvir (PIB) identified phosphomethyl analog 2 and trimethyl-lock (TML) prodrug 9. The prodrug moiety is attached to a benzimidazole nitrogen via an oxymethyl linkage… read more here.
Keywords: inhibitor pibrentasvir; prodrug; ns5a inhibitor; hcv ns5a ... See more keywords
Interplay of Amino Acid Residues at Positions 28 and 31 in NS5A Defines Resistance Pathways in Hepatitis C Virus Genotype 2
Sign Up to like & getrecommendations! Published in 2019 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.01269-19
Abstract: Hepatitis C virus (HCV) genotype 2 (GT2) represents approximately 9% of all viral infections globally. While treatment outcomes for GT2-infected patients have improved substantially with direct-acting antiviral agents (DAAs) compared to alpha interferon, the presence… read more here.
Keywords: resistance; hepatitis virus; genotype; inhibitor ... See more keywords